GDTC CytoMed Therapeutics (GDTC) Insider Trading, Ownership & Congress Trades
What the filings say about GDTC
CytoMed Therapeutics insider trades (Form 4)
Over the last 180 days, CytoMed Therapeutics Ltd insiders bought a net $728.8K of stock across 5 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 14, 2026.
- -4.4% median (-4.4% mean) 90-day return after 2 previous buys.
- The trade is 15.9% of the 630,324 shares held after it.
- No other insider bought within 30 days.
Insider activity: Director Choo Chee Kong bought about $150.0K of GDTC on Jul 20, 2026.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 14, 2026.
- -4.4% median (-4.4% mean) 90-day return after 2 previous buys.
- The trade is 15.9% of the 630,324 shares held after it.
- No other insider bought within 30 days.
Insider activity: Director Choo Chee Kong bought about $150.0K of GDTC on Jul 20, 2026.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 13, 2026.
- The trade is 18.9% of the 530,324 shares held after it.
- No other insider bought within 30 days.
Insider activity: Director Choo Chee Kong bought about $150.0K of GDTC on Jul 14, 2026, the largest insider purchase at the company on our record.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 13, 2026.
- The trade is 18.9% of the 530,324 shares held after it.
- No other insider bought within 30 days.
Insider activity: Director Choo Chee Kong bought about $150.0K of GDTC on Jul 14, 2026, the largest insider purchase at the company on our record.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 26.0% of the 430,324 shares held after it.
- No other insider bought within 30 days.
Insider activity: Director Choo Chee Kong bought about $128.8K of GDTC on May 13, 2026, the largest insider purchase at the company on our record.Why it matters
Watch GDTC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns GDTC: institutional holders (13F)
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in GDTC
Activist and 5% holders (13D/13G)
GDTC planned insider sales (Form 144)
GDTC financials
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Net income | -$4.0M | -$2.5M | -$4.1M | -$3.1M |
GDTC Stock Sonar score 2/7 axes
Find similar shapesCompare2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
GDTC filings, in plain words
Are CytoMed Therapeutics insiders buying or selling GDTC?
In the 180 days to 2026-10-27, CytoMed Therapeutics insiders were net buyers, a net $728.8K across purchases and sales reported on Form 4, by 1 buyer.
Are there planned insider sales of GDTC?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $103.3K of stock; the latest, by mDR Ltd, was filed 2026-08-11.
Read the full summary
In the 180 days to 2026-10-27, CytoMed Therapeutics insiders were net buyers of GDTC, a net $728.8K across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $728.8K, came from a holder of 10% or more rather than an officer or director. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $103.3K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
